# **Product** Data Sheet

### PF-06291874

**Cat. No.:** HY-19947

CAS No.: 1393124-08-7 Molecular Formula:  $C_{26}H_{28}F_3N_3O_4$ 

Molecular Weight: 503.51

Target: Glucagon Receptor

Pathway: GPCR/G Protein

Storage: Powder -20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

#### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: ≥ 30 mg/mL (59.58 mM)

\* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.9861 mL	9.9303 mL	19.8606 mL
	5 mM	0.3972 mL	1.9861 mL	3.9721 mL
	10 mM	0.1986 mL	0.9930 mL	1.9861 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.13 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (4.13 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.13 mM); Clear solution

## **BIOLOGICAL ACTIVITY**

**Description** PF-06291874 is a highly potent, non-peptide and orally active glucagon receptor antagonist. PF-06291874 is under the study for type 2 diabetes mellitus (T2DM)<sup>[1][2]</sup>.

In Vivo

PF-06291874 exposure is approximately dose-proportional with a half-life of -19.7-22.7 h. PF-06291874 has a fast on and off rate. PF-06291874 is highly bound to human plasma protein, with a mean free fraction of -0.55%<sup>[3]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### **REFERENCES**

- [1]. Esther C.Y. Lee et al. Identification of a novel conformationally constrained glucagon receptor antagonist. Bioorg Med Chem Lett, 2014 Feb 1, 24(3):839-44.
- [2]. Derek J Nunez, et al. Glucagon receptor as a drug target: A witches' brew of eye of newt (peptides) and toe of frog (receptors). Diabetes Obes Metab. 2018 Feb;20(2):233-237.
- [3]. D J Kazierad, et al. Effects of multiple ascending doses of the glucagon receptor antagonist PF-06291874 in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2016 Aug;18(8):795-802.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com